Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - zidovudine, quantity: 100 mg - capsule - excipient ingredients: sodium starch glycollate; microcrystalline cellulose; maize starch; magnesium stearate; titanium dioxide; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid; potassium hydroxide - retrovir is indicated for: . treatment of adult patients with severe symptomatic human immunodeficiency virus infection (aids or advanced aids related complex); . treatment of other hiv-positive adult patients with less than 500 cd4 cells/mm3. notes: (1) the limited available data currently support the extended use of retrovir (indication 2 above). (2) the optimal dosage for these indications has not been established. . combination therapy in advanced hiv infection. the addition of hivid (zalcitabine) may be considered for the management of adult patients with advanced hiv infection and cd4 + cell counts less than or equal to 200/mm3, who have received retrovir monotherapy for less than 12 months. retrovir monotherapy is still indicated as initial therapy for adult patients with hiv infection who fulfil the approved indications. new indications approved 7th february 1997: retrovir (zidovudine) is indicated for the treatment of hiv infection, alone and in combination with other antiretroviral therapies. the optimum dosage for this indication has not been established.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - probenecid, quantity: 500 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; stearic acid; magnesium stearate; maize starch; microcrystalline cellulose; povidone; macrogol 8000; hypromellose; macrogol 400; titanium dioxide; sunset yellow fcf; polysorbate 80; quinoline yellow - indications as at 25 may 2000 : gout - probenecid is a uricosuric agent for the treatment of hyperuricaemia in all stages of gout and gouty arthritis except an acute attack. asymptomatic hyperuricaemia seems to occur in a significant percentage of relatives of gouty patients. probenecid may be given prophylactically to these people to forestall gouty attacks and urate deposition in tissues. by virtue of its effective uricosuric activity, probenecid may be used to control the hyperuricaemia induced or aggravated by many diuretics employed for the treatment of oedema and hypertension (e.g. thiazides and smiliar diuretics). b-lactam antibiotic therapy - probenecid is indicated for the elevation and prolongation of plasma levels by whatever route the antibiotic is given. a two-to-fourfold increase in plasma levels has been demonstrated for benzylpenicillin, phenoxymethylpenicillin, the synthetic penicillins, ampicillin, methicillin, oxacillin, cloxacillin, nafcillin, carbenicillin, and for the cephamycin, mefoxin (cefoxitin sodium, msd), and the cephalosporins, cephalothin, cephalexin and cephaloglycin. because of its mechanisim of action, probenecid is not recommended in conjunction with a b-lactam antibiotic in the presence of known renal impairment. concurrent treatment with cidofovir for cmv retinitis in hiv patients. probenecid is recommended to be administered concomitantly with cidofovir, as the combination reduces the potential for nephrotoxicity associated with cidofovir.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - zidovudine, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: citric acid; glycerol; maltitol solution; purified water; sodium benzoate; saccharin sodium; flavour - (1) treatment of adult patients with severe symptomatic human immunodeficiency virus infection (aids or advanced aids related complex). (2) treatment of other hiv-positive adult patients with less than 500 cd4 cells/mm3. new indications as at 11 may 1994: retrovir is indicated for: . treatment of adult patients with severe symptomatic human immunodeficiency virus infection (aids or advanced aids related complex); . treatment of other hiv-positive adult patients with less than 500 cd4 cells/mm3. notes: (1) the limited available data currently support the extended use of retrovir (indication 2 above). (2) the optimal dosage for these indications has not been established . combination therapy in advanced hiv infection: the addition of hivid (zalcitabine) may be considered for the management of adult patients with advanced hiv infection and cd4 + cell counts less than or equal to 200/mm3, who have received retrovir monotherapy for less than 12 months. retrovir monotherapy is still indicated as initial therapy f

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - arsenic trioxide, quantity: 12 mg - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - for the induction of remission and consolidation in patients with acute promyelocytic leukaemia (apl) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.,for the induction of remission and consolidation in patients with previously untreated acute promyelocytic leukaemia (apl) in combination with all-trans retinoic acid (atra) and/or chemotherapy and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - valganciclovir, quantity: 450 mg - tablet, film coated - excipient ingredients: povidone; stearic acid; microcrystalline cellulose; crospovidone; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir is indicated for the treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids). valganciclovir is indicated for the prophylaxis of cmv infection and disease following solid organ transplantation in patients at risk of cmv disease.

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - methotrexate - oral tablet - 10mg

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - methotrexate - oral tablet - 2.5mg

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

teva b.v. - arsenic trioxide - leukemia, promyelocytic, acute - antineoplastic agents - trisenox is indicated for induction of remission, and consolidation in adult patients with:newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 103/µl) in combination with all‑trans‑retinoic acid (atra)relapsed/refractory acute promyelocytic leukaemia (apl) (previous treatment should have included a retinoid and chemotherapy)characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rar-alpha) gene.the response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.

Singapura - Inggeris - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - valganciclovir - tablet, film coated - 450 mg - valganciclovir 450 mg

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

clinigen limited - foscarnet sodium (unii: 964ys0oog1) (foscarnet - unii:364p9rvw4x) - foscarnet sodium 24 mg in 1 ml - foscavir is indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids). combination therapy with foscavir and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. safety and efficacy of foscavir have not been established for treatment of other cmv infections (e.g., pneumonitis, gastroenteritis); congenital or neonatal cmv disease; or nonimmunocompromised individuals. foscavir is indicated for the treatment of acyclovir-resistant mucocutaneous hsv infections in immunocompromised patients. safety and efficacy of foscavir have not been established for treatment of other hsv infections (e.g., retinitis, encephalitis); congenital or neonatal hsv disease; or hsv in nonimmunocompromised individuals. foscavir is contraindicated in patients with clinically significant hypersensitivity to foscarnet sodium.